Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.

480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).

Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.